CompletedNCT00259870
SB-773812, olanzapine, or placebo for acute schizophrenia
About this title
Read the official source — NCT00259870This study evaluated the safety and effectiveness of SB-773812 for people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SB-773812 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 338
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Belgium, Costa Rica, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00259870
- Official title
Show the full official title
A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Cerritos, United States · Garden Grove, United States
37 more locations
- National City, United States
- San Diego, United States
- Upland, United States
- New Haven, United States
- Washington D.C., United States
- North Miami, United States
- Clementon, United States
- Kenilworth, United States
- Albuquerque, United States
- Orangeburg, United States
- Butner, United States
- Cincinnati, United States
- Bellaire, United States
- San Antonio, United States
- Falls Church, United States
- Liège, Belgium
- Montignies-sur-Sambre, Belgium
- San José, Costa Rica
- Brno, Czechia
- Lnáře, Czechia
- Prague, Czechia
- Ahmedabad, India
- Bangalore, India
- Hyderabad, India
- Lucknow, India
- Ludhiana, India
- Mangalore, India
- Pune, India
- Tirupati, India
- Lima, Peru
- Leningraskaya Region, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Smolensk, Russia
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SB-773812 for people with schizophrenia.
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including SB-773812 and Olanzapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia